» Articles » PMID: 38261132

On Spillovers in Economic Evaluations: Definition, Mapping Review and Research Agenda

Overview
Specialty Health Services
Date 2024 Jan 23
PMID 38261132
Authors
Affiliations
Soon will be listed here.
Abstract

An important issue in economic evaluations is determining whether all relevant impacts are considered, given the perspective chosen for the analysis. Acknowledging that patients are not isolated individuals has important implications in this context. Increasingly, the term "spillovers" is used to label consequences of health interventions on others. However, a clear definition of spillovers is lacking, and as a result, the scope of the concept remains unclear. In this study, we aim to clarify the concept of spillovers by proposing a definition applicable in health economic evaluations. To illustrate the implications of this definition, we highlight the diversity of potential spillovers through an expanded impact inventory and conduct a mapping review that outlines the evidence base for the different types of spillovers. In the context of economic evaluations of health interventions, we define spillovers as all impacts from an intervention on all parties or entities other than the users of the intervention under evaluation. This definition encompasses a broader range of potential costs and effects, beyond informal caregivers and family members. The expanded impact inventory enables a systematic approach to identifying broader impacts of health interventions. The mapping review shows that the relevance of different types of spillovers is context-specific. Some spillovers are regularly included in economic evaluations, although not always recognised as such, while others are not. A consistent use of the term "spillovers", improved measurement of these costs and effects, and increased transparency in reporting them are still necessary. To that end, we propose a research agenda.

Citing Articles

Socioeconomic burden of cystic fibrosis in Canada.

Laflamme O, Johnson N, Steele K, Chavez L, Cheng S, Rabin H BMJ Open Respir Res. 2024; 11(1).

PMID: 39122474 PMC: 11331897. DOI: 10.1136/bmjresp-2024-002309.


Blockchain Applications in the Pharmaceutical Industry.

Gaynor M, Gillespie K, Roe A, Crannage E, Tuttle-Newhall J Blockchain Healthc Today. 2024; 7.

PMID: 38715760 PMC: 11073477. DOI: 10.30953/bhty.v7.298.

References
1.
Al-Janabi H, Flynn T, Coast J . Estimation of a preference-based carer experience scale. Med Decis Making. 2010; 31(3):458-68. DOI: 10.1177/0272989X10381280. View

2.
Goranitis I, Coast J, Day E, Copello A, Freemantle N, Frew E . Maximizing Health or Sufficient Capability in Economic Evaluation? A Methodological Experiment of Treatment for Drug Addiction. Med Decis Making. 2016; 37(5):498-511. DOI: 10.1177/0272989X16678844. View

3.
Mattingly 2nd T, Diaz Fernandez V, Seo D, Melgar Castillo A . A review of caregiver costs included in cost-of-illness studies. Expert Rev Pharmacoecon Outcomes Res. 2022; 22(7):1051-1060. DOI: 10.1080/14737167.2022.2080056. View

4.
Itzler R, Chen P, Lac C, El Khoury A, Cook J . Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan. J Med Econ. 2011; 14(6):748-58. DOI: 10.3111/13696998.2011.614303. View

5.
Makai P, Brouwer W, Koopmanschap M, Stolk E, Nieboer A . Quality of life instruments for economic evaluations in health and social care for older people: a systematic review. Soc Sci Med. 2014; 102:83-93. DOI: 10.1016/j.socscimed.2013.11.050. View